Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Financing Activities (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Cash from Financing Activities data on record, last reported at $5.2 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 1826.76% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $27.7 million, down 73.9%, while the annual FY2024 figure was $104.1 million, 181.02% up from the prior year.
  • Cash from Financing Activities reached $5.2 million in Q3 2025 per ABEO's latest filing, down from $10.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $73.7 million in Q2 2024 and bottomed at -$299000.0 in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $13.8 million, with a median of $6.6 million recorded in 2023.
  • The widest YoY moves for Cash from Financing Activities: up 636100.0% in 2024, down 101.3% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $16.3 million in 2021, then skyrocketed by 161.87% to $42.8 million in 2022, then crashed by 82.54% to $7.5 million in 2023, then dropped by 28.83% to $5.3 million in 2024, then fell by 2.84% to $5.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $5.2 million in Q3 2025, $10.5 million in Q2 2025, and $6.8 million in Q1 2025.